News

DENVER, Colo. — Oncology researchers must “lace up our running shoes,” to keep up with the fast pace of lung cancer research, said Dr. David R. Gandara, Professor of Medicine, Division of Hematology/Oncology, director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center, Sacramento, Calif.

DENVER, Colo. — Researchers expect that the administration of molecular-targeted therapies will be considered for the advanced-stage of adenocarcinoma in young lung cancer patients, according to a presentation by Dr. Kosuke Tanaka, department of Cancer Genetics, Nagoya University Graduate School of Medicine; Division of Molecular Oncology, Aichi Cancer Center Research Institute, Japan. Dr. Tanaka presented his data at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver.

DENVER, Colo. — Research presented today shows that certain lung cancer patients under age 40 are associated with an increased chance for a targeted genomic alteration that may lead to more effective treatments. Dr. Barbara Gitlitz, Associate Professor of Clinical Medicine at the University of Southern California Keck School of Medicine in Los Angeles unveiled the findings at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. — The percentage of patients with non-small cell lung cancer (NSCLC) who never smoked is on the rise, according to a report conducted of lung cancer patients in three hospitals in Texas and Tennessee. Dr. Lorraine Pelosof, Assistant Professor, UT Southwestern Medical Center, Dallas, Texas presented the research at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. – Lung cancer researchers in Great Britain discovered that the incidence of people who never smoked and were diagnosed with non-small cell lung cancer (NSCLC) increased from 13 percent to 28 percent in a seven-year period. The research was presented today by Dr. Eric Lim, Royal Brompton & Harefield NHS Foundation Trust, London at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. – If cancer patients are to receive optimal treatment, clinicians must have an accurate histologic classification of the tumor and know its genetic characteristics, said William D. Travis, M.D., attending thoracic pathologist, Department of Pathology, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Travis made his remarks today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

Pages